CA2318987A1 - Immune effector cell hybrids - Google Patents

Immune effector cell hybrids Download PDF

Info

Publication number
CA2318987A1
CA2318987A1 CA002318987A CA2318987A CA2318987A1 CA 2318987 A1 CA2318987 A1 CA 2318987A1 CA 002318987 A CA002318987 A CA 002318987A CA 2318987 A CA2318987 A CA 2318987A CA 2318987 A1 CA2318987 A1 CA 2318987A1
Authority
CA
Canada
Prior art keywords
cells
antigen
immune effector
population
effector cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002318987A
Other languages
English (en)
French (fr)
Inventor
Bruce L. Roberts
Charles A. Nicolette
Donald Kufe
Jianlin Gong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2318987A1 publication Critical patent/CA2318987A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002318987A 1998-01-26 1999-01-25 Immune effector cell hybrids Abandoned CA2318987A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8835798P 1998-01-26 1998-01-26
US60/088,357 1998-01-26
US8004198P 1998-03-31 1998-03-31
US60/080,041 1998-03-31
PCT/US1999/001464 WO1999037313A1 (en) 1998-01-26 1999-01-25 Immune effector cell hybrids

Publications (1)

Publication Number Publication Date
CA2318987A1 true CA2318987A1 (en) 1999-07-29

Family

ID=26762993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318987A Abandoned CA2318987A1 (en) 1998-01-26 1999-01-25 Immune effector cell hybrids

Country Status (5)

Country Link
EP (1) EP1071436A4 (cg-RX-API-DMAC10.html)
JP (2) JP2002500872A (cg-RX-API-DMAC10.html)
AU (1) AU2339299A (cg-RX-API-DMAC10.html)
CA (1) CA2318987A1 (cg-RX-API-DMAC10.html)
WO (1) WO1999037313A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
CN1353575A (zh) * 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞
ES2306771T3 (es) 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc Un metodo de terapia celular para tratamiento de tumores.
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
FR2828934B1 (fr) * 2001-08-27 2004-08-13 Inst Nat Sante Rech Med Test de l'immunite cellulaire par des peptides fixes sur support solide
AU2003275767A1 (en) * 2002-11-07 2004-06-07 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride

Also Published As

Publication number Publication date
EP1071436A1 (en) 2001-01-31
JP2002500872A (ja) 2002-01-15
EP1071436A4 (en) 2003-08-27
JP2009195235A (ja) 2009-09-03
AU2339299A (en) 1999-08-09
WO1999037313A1 (en) 1999-07-29

Similar Documents

Publication Publication Date Title
US20020164346A1 (en) Altered peptide ligands
US20020018766A1 (en) Genes differentially expressed in cancer cells to design cancer vaccines
JP2015171389A (ja) 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激
US7601342B2 (en) Cell fusions and methods of making and using the same
US20020041868A1 (en) Cell fusions and methods of making and using the same
JP2009195235A (ja) 免疫エフェクター細胞ハイブリッド
US20020006397A1 (en) In VIVO loading of MHC
AU3102299A (en) Compositions and methods for gene-based vaccines to provoke T cell responses
AU3102999A (en) Induction of immunity against tumor self-antigens
AU2003271378B2 (en) Immune effector cell hybrids
AU2007231612B2 (en) Immune effector cell hybrids
AU3102799A (en) Enhanced anti-tumor immunity
JP2003521936A5 (cg-RX-API-DMAC10.html)
AU2007201829A1 (en) Immune effector cell hybrids
EP1063891A2 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
US20020065241A1 (en) Antigenic peptide concatomers
AU759765B2 (en) Compositions and methods for antigen-specific vaccination
US7014848B1 (en) Enhanced anti-tumor immunity
AU2002250114A1 (en) Altered peptide ligands

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued